- Home
- IHS vs HRMY Comparison
IHS vs HRMY Comparison
Compare IHS & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IHS | HRMY |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.5B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IHS | HRMY |
|---|---|---|
| Price | $8.44 | $41.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | $8.29 | ★ $44.11 |
| AVG Volume (30 Days) | ★ 1.2M | 805.4K |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | N/A | ★ 1.84 |
| Revenue | N/A | ★ $868,453,000.00 |
| Revenue This Year | $17.26 | $19.75 |
| Revenue Next Year | $7.87 | $12.88 |
| P/E Ratio | ★ $5.85 | $22.88 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $5.71 | $25.52 |
| 52 Week High | $8.95 | $43.49 |
Technical Indicators
Market Signals| Indicator | IHS | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 54.13 | 57.37 |
| Support Level | $8.11 | $40.92 |
| Resistance Level | $8.52 | $43.49 |
| Average True Range (ATR) | 0.04 | 1.12 |
| MACD | -0.01 | -0.12 |
| Stochastic Oscillator | 13.64 | 30.95 |
Price Performance
Historical ComparisonAbout IHS IHS Holding Limited
IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria and Sub-Saharan Africa. The majority of its revenue is derived from Nigeria.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.